Individualized, Target-Driven Treatment Of Children With Idiopathic Short Stature
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
To demonstrate that an individualized, formula-based Genotropin regimen for children with
Idiopathic Short Stature will lead to a targeted height gain (to reach the target of 10th
percentile (%), or -1.3 SDS) during 24 months of treatment. The endpoint at 4 years is to
explore treatment efficiency over four years of two formula-based dose regimens (sub-arms)
compared to standard treatment